The current widespread misconceptions regarding the long-term benefits of HPV vaccination appear to have resulted from (1) significant misinterpretation of clinical trials data (i.e., invalid and premature extrapolations from (often dubious) surrogate markers such as CIN 2); and (2) biased and selective reporting of clinical trial results (i.e., reporting combined efficacy against CIN 1-3 or CIN 2/3, failure to report p-values, exclusion of certain efficacy figures from official clinical trials publications, such as those related to study subgroups in which efficacy might be lower or even negative, e.g., those with pre-existing HPV-16/18 infections). While all of these factors give an inaccurate and misleading picture of overall effectiveness of HPV vaccines, exclusion of negative efficacy figures from peer-reviewed publications (Table 2) additionally precludes an objective and independent assessment of their true prophylactic value. Of further concern are misleading opinions on HPV vaccine safety, based solely on manufacturer-sponsored, type-2 error-biased clinical trials designs. Download Full Text: eurekaselect/106059/article
Posted on: Thu, 23 Oct 2014 16:30:50 +0000
Trending Topics
Recently Viewed Topics
© 2015